-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Synexis, a partner of Hausen Pharmaceuticals, announced that the US Food and Drug Administration has approved a new broad-spectrum antifungal drug Brexafemme, which is an oral drug for the treatment of female patients with vulvovaginal candidiasis.
Vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection caused by Candida, is the second most common cause of vaginitis.
At present, the treatment of VVC includes several topical azole antifungals (clotrimazole, miconazole, etc.
It is reported that on February 17 this year, Hausen Pharmaceuticals and Scinexis signed a strategic cooperation agreement to obtain ibrexafungerp's exclusive rights in the development and commercialization of ibrexafungerp in Greater China (including Hong Kong, Macau and Taiwan).